trial · primary record
Teclistamab
Multiple Myeloma
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 108 |
| Primary completion | 2028-01-13 |
| Primary endpoint | Maximum Observed Serum Concentration (Cmax) of First Treatment Dose of Teclistamab |
| Registry ID | NCT06425991 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:56:17.683Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06425991
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Teclistamab · compound